Welcome to our dedicated page for Spyre Therapeutics SEC filings (Ticker: SYRE), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on Spyre Therapeutics's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time SEC filing updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into Spyre Therapeutics's regulatory disclosures and financial reporting.
Tang Capital Management, Kevin Tang and related funds report a 2.4% passive stake in Spyre Therapeutics, Inc. common stock. They disclose beneficial ownership of 1,892,200 shares, with no sole voting or dispositive power and shared authority over all reported shares.
The group notes that Spyre had 77,592,130 shares outstanding as of October 29, 2025 to calculate this percentage. They also certify the shares were not acquired, and are not held, to change or influence control of Spyre Therapeutics.
Spyre Therapeutics, Inc.'s Chief Executive Officer and director Turtle Cameron reported two open-market sales of common stock. On February 2, 2026, Cameron sold 957 shares at a weighted average price of $31.82 and 14,043 shares at a weighted average price of $32.87, both coded as open-market sales.
The filing states these transactions were executed under a Rule 10b5-1 trading plan adopted on June 20, 2025. After these sales, Cameron beneficially owned 657,540 shares of common stock, which include shares scheduled to vest over approximately one year and shares acquired under the company’s employee stock purchase plan.
Spyre Therapeutics, Inc. director Michael Thomas Henderson reported receiving 63,227 shares of common stock on January 21, 2026. The shares were received for no cash consideration through a pro-rata distribution from a limited liability company in which he is a member, rather than through an open-market purchase. Following this distribution, he beneficially owns 168,606 shares of Spyre Therapeutics common stock in direct form.
Spyre Therapeutics, Inc. reported an insider equity award to its Chief Financial Officer, Scott L. Burrows, in a Form 4 filing. On January 9, 2026, he was granted a stock option to purchase 140,000 shares of Spyre Therapeutics common stock at an exercise price of $30.61 per share. The option is a derivative security and is held directly.
The filing states that this option will vest in equal monthly installments over four years, and each vesting installment is conditioned on his continued employment with the company at the relevant vesting date. Following this grant, Burrows beneficially owns 140,000 stock options, with the option scheduled to expire on January 9, 2036.
Spyre Therapeutics, Inc. reported that its Chief Executive Officer and director, Turtle Cameron, received a grant of stock options on 01/09/2026. The award covers 528,000 stock options, each representing the right to purchase one share of Spyre Therapeutics common stock at an exercise price of $30.61 per share, with an expiration date of 01/09/2036.
According to the filing, these options will vest in equal monthly installments over four years, and each vesting date is conditioned on Cameron’s continued employment with the company. Following this grant, Cameron beneficially owns 528,000 derivative securities directly in the form of these stock options.
Spyre Therapeutics, Inc. reported that its Chief Medical Officer, Sloan Sheldon, received a stock option grant on January 9, 2026. The award covers options to purchase 140,000 shares of Spyre’s common stock at an exercise price of $30.61 per share, expiring on January 9, 2036. Following this grant, Sloan Sheldon beneficially owns 140,000 stock options directly. The option will vest in equal monthly installments over four years, conditioned on continued employment with the company at each vesting date.
Spyre Therapeutics, Inc. reported a new stock option grant to an executive officer. Chief Legal Officer and Corporate Secretary Heidy King-Jones received a stock option covering 140,000 shares of Spyre Therapeutics common stock on 01/09/2026.
The option has an exercise price of $30.61 per share and was reported as acquired with no cash paid for the option itself. The grant vests in equal monthly installments over four years, conditioned on her continued employment with the company at each vesting date. Following this grant, she beneficially owns 140,000 derivative securities directly in the form of this option.
Spyre Therapeutics, Inc. furnished a current report describing a new press release and an updated corporate presentation made available on its website. These materials include updates on the company’s ongoing clinical trials and the appointment of Kate Tansey Chevlen as Chief Commercial Officer.
The press release (Exhibit 99.1) and the January 2026 corporate presentation (Exhibit 99.2) are provided as exhibits and are treated as furnished rather than filed under securities laws, which affects how they are incorporated into other regulatory documents.
Spyre Therapeutics (SYRE) reported insider activity: the Chief Executive Officer and Director sold 45,000 shares of common stock on 11/03/2025 under a Rule 10b5-1 trading plan adopted on June 20, 2025. The sales comprised 28,155 shares at a weighted average price of $23.13 (range $22.51–$23.50) and 16,845 shares at a weighted average price of $23.66 (range $23.51–$24.04). Following these transactions, the reporting person beneficially owns 701,907 shares, which includes 188,743 shares scheduled to vest in monthly installments over approximately one year, subject to continued service.
Spyre Therapeutics (SYRE) filed an 8-K announcing two updates: it furnished a press release with financial results for the quarter ended September 30, 2025, and reported positive interim Phase 1 data for SPY003, an extended half-life monoclonal antibody targeting IL‑23.
The first‑in‑human, randomized, double‑blind, placebo‑controlled study enrolled 59 healthy adults across single‑ascending, multiple‑dose, and a Chinese ethnobridging cohort. SPY003 was well tolerated at all dose levels, with two Grade 2 or higher treatment‑emergent adverse events deemed not treatment‑related and no serious adverse events; headache was the only event seen in two or more subjects.
Pharmacokinetic data showed an approximate 85‑day half‑life with dose proportionality and limited intrasubject variability, described as more than three times risankizumab’s published half‑life. The company stated this profile supports the potential for quarterly or twice‑yearly maintenance dosing via a single subcutaneous injection. No apparent impact of anti‑drug antibodies on PK was observed. Spyre noted plans to advance SPY003 into the SKYLINE Phase 2 platform study.